GB2430156A — Bisphosphonate formulation

USPTO Abstract

A formulation comprising a bisphosphonate in combination with an antifoaming agent to reduce surface tension and/or foaming in the stomach, leading to reduced reflux and oesophagal irritation in use. The composition is useful for the treatment of osteoporosis. The preferred antifoaming agents are polydimethylsiloxanes particularly dimethicone, simethicone or a combination thereof. Preferred phosphonates are selected from alendronic acid, alendronates, disodium etidronate, disodium pamidronate, ibandronic acid, risedronate sodium, sodium clodronate, strontium ranelate, tiludronic acid and zoledronic acid. Particularly preferred are alendronic acid, alendronate, risedronate and etidronate. The formulation may additionally comprise: an antacid, such as a carbonate, trisilicate or oxide salt; a vitamin D derivative, for example ergocalciferol, cholecaldciderol, dihydrotachysterol, alfacalcidol and calcitriol; or a calcium supplement, for example calcium gluconate, calcium chloride etc. A kit comprising the bisphosphonate and antifoaming agent is also outlined.